JPWO2022059785A1 - - Google Patents

Info

Publication number
JPWO2022059785A1
JPWO2022059785A1 JP2022550635A JP2022550635A JPWO2022059785A1 JP WO2022059785 A1 JPWO2022059785 A1 JP WO2022059785A1 JP 2022550635 A JP2022550635 A JP 2022550635A JP 2022550635 A JP2022550635 A JP 2022550635A JP WO2022059785 A1 JPWO2022059785 A1 JP WO2022059785A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550635A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022059785A1 publication Critical patent/JPWO2022059785A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06Quantitative determination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
JP2022550635A 2020-09-18 2021-09-17 Pending JPWO2022059785A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020157940 2020-09-18
PCT/JP2021/034399 WO2022059785A1 (ja) 2020-09-18 2021-09-17 免疫チェックポイント阻害剤に対する応答を予測する方法

Publications (1)

Publication Number Publication Date
JPWO2022059785A1 true JPWO2022059785A1 (https=) 2022-03-24

Family

ID=80776174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550635A Pending JPWO2022059785A1 (https=) 2020-09-18 2021-09-17

Country Status (3)

Country Link
JP (1) JPWO2022059785A1 (https=)
TW (1) TW202227643A (https=)
WO (1) WO2022059785A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025048570A1 (ko) * 2023-08-31 2025-03-06 의료법인 성광의료재단 신장암에서 면역 관문 억제제의 치료 반응성 예측 마커 및 이를 이용한 치료 반응성 예측 방법
EP4617665A1 (en) * 2024-03-14 2025-09-17 Centre National de la Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma
WO2025191110A1 (en) * 2024-03-14 2025-09-18 Centre National De La Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016175275A1 (ja) * 2015-04-30 2016-11-03 国立大学法人京都大学 Pd-l1(cd274)の異常を指標としたpd-1/pd-l1阻害剤の治療効果予測方法
JP2018505658A (ja) * 2014-12-09 2018-03-01 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
WO2019191390A2 (en) * 2018-03-28 2019-10-03 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
WO2019230919A1 (ja) * 2018-05-31 2019-12-05 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
JP2020500151A (ja) * 2016-09-27 2020-01-09 ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505658A (ja) * 2014-12-09 2018-03-01 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
WO2016175275A1 (ja) * 2015-04-30 2016-11-03 国立大学法人京都大学 Pd-l1(cd274)の異常を指標としたpd-1/pd-l1阻害剤の治療効果予測方法
JP2020500151A (ja) * 2016-09-27 2020-01-09 ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
WO2019191390A2 (en) * 2018-03-28 2019-10-03 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
WO2019230919A1 (ja) * 2018-05-31 2019-12-05 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SONG, P. ET AL.: "Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy i", THORACIC CANCER, vol. 11, JPN6021048556, 23 April 2020 (2020-04-23), pages 1621 - 1632, ISSN: 0005619156 *
ZHENG YI ET AL.: "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carci", JOURNAL OF IMMUNOTHERAPY OF CANCER, vol. 7, JPN6025023838, 2019, pages 193, ISSN: 0005619158 *
市川将隆,他: "腸内細菌と免疫および悪性腫瘍との関連", 癌と化学療法, vol. 46, no. 12, JPN6021048555, 2019, pages 1807 - 1813, ISSN: 0005619157 *

Also Published As

Publication number Publication date
TW202227643A (zh) 2022-07-16
WO2022059785A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2022059785A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20230417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260428